Key result
MRA therapy fails to reduce mortality in post-MI patients with acute heart failure.
Why the study?
Clinical presentations, predictors, and outcomes of MRA-eligible acute heart failure patients in Saudi Arabia were not well characterized, and the impact of MRA treatment on long-term survival was uncertain.
Cohort (n=387)
Yes
Answers are grounded in this paper and cite their sources.
Does not support routine MRA use for mortality reduction in acute HF post-MI; leaves open efficacy in randomized trials.
Mineralocorticoid receptor antagonist (MRA) therapy is indicated after myocardial infarction in patients with acute heart failure (AHF) with an ejection fraction ≤40% and lacking contraindications. We analyzed clinical presentations, predictors, and outcomes of MRA-eligible patients within a prospective registry of patients with AHF from 18 hospitals in Saudi Arabia, from 2009 to 2010. For this subgroup, mortality rates were followed until 2013, and the clinical characteristics, management, predictors, and outcomes were compared between MRA-treated and non-MRA-treated patients. Of 2609 patients with AHF, 387 (14.8%) were MRA eligible, of which 146 (37.7%) were prescribed MRAs. Compared with non-MRA-treated patients, those prescribed MRAs more commonly exhibited non-ST-segment elevation myocardial infarction, acute on chronic heart failure, past history of ischemic heart disease, and severe left ventricular systolic dysfunction; were more commonly administered oral furosemide and digoxin; and had higher in-hospital recurrent congestive HF rates. Mortality did not significantly differ ( P > .05) between groups. In Saudi Arabia, 37.7% of eligible patients received MRA treatment, which is higher than that in developed countries. The lack of long-term survival benefit raises concerns about systematic problems, for example, proper follow-up and management after hospital discharge, warranting further investigation.
No takes yet. Share an insight, caveat, or question.
Alshamiri et al. (2017) conducted a cohort in Acute heart failure (n=387). Mineralocorticoid receptor antagonist (MRA) therapy vs. Non-MRA-treated patients was evaluated on Mortality (p=> .05). Mineralocorticoid receptor antagonist therapy did not reduce mortality compared to no MRA treatment among eligible patients with acute heart failure post-myocardial infarction.
Synapse has enriched 10 related papers. Consider them for comparative context: